



PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
SHEET 1 OF 10	Examiner	Williams, Leonard M.
	Attorney Docket No.	ACADIA.030A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/LW/	1	4,138,492	2/6/1979	Noverola, et al.	
	2	4,255,432	3/10/1981	Kluge, et al.	
	3	4,332,804	6/1/1982	Clark	
	4	4,353,900	10/12/1982	Clark	
	5	4,353,901	10/12/1982	Clark	
	6	4,367,232	1/4/1983	Boix-Iglesias, et al.	
	7	5,025,013	6/18/1991	Barreau, et al.	
	8	5,214,055	5/25/1993	Peglion, et al.	
	9	5,461,066	10/24/1995	Gericke, et al.	
	10	5,595,872	1/21/1997	Wetterau II, et al.	
	11	5,621,010	4/15/1997	Sueda, et al.	
	12	5,795,894	8/18/1998	Shue, et al.	
	13	5,869,488	2/9/1999	Shue, et al.	
	14	6,107,324	8/22/2000	Behan, et al.	
	15	6,140,509	10/31/2000	Behan, et al.	
	16	7,022,698	4/4/2006	Hamied, et al.	
	17	7,041,667	5/9/2006	Armour, et al.	
	18	2004/0213816 A1	10/28/2004	Weiner, et al.	
	19	2005/0148018 A1	7/7/2005	Weiner, et al.	
	20	2005/0244862 A1	11/3/2005	Brann	
	21	2006/0106063 A1	5/18/2006	Thygesen, et al.	
	22	2006/0111399 A1	5/25/2006	Thygesen, et al.	
	23	2006/0205780 A1	9/14/2006	Thygesen, et al.	
	24	2006/0205781 A1	9/14/2006	Thygesen, et al.	
	25	2006/0264466 A1	11/23/2006	Weiner, et al.	
	26	2006/0286610 A1	12/21/2006	Brann	
/LW/	27	2006/0292606 A1	12/28/2006	Brann	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
SHEET 2 OF 10	Examiner	Williams, Leonard M.
	Attorney Docket No.	ACADIA.030A

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/LW/	28	CA 984843	3/2/1976	John Wyeth & Brother Limited		
	29	EP 0 005 318 A1	11/14/1979	Janssen Pharm.		
	30	EP 0 061 333 A1	9/29/1982	Syntex (U.S.A.) Inc.		
	31	EP 0 379 441 A1	7/25/1990	Rhone-Poulenc Sante		
	32	EP 0 548 015 A1	6/23/1993	Ciba-Geigy AG		
	33	EP 0 625 507 A2	11/23/1994	Nisshin Flour Milling Co., Ltd.		
	34	HU 157325	3/19/1998	Rudolf, et al.		
	35	WO 97/08166 A1	3/6/1997	Schering Corporation		
	36	WO 97/11940 A1	4/3/1997	Eli Lilly and Company		
	37	WO 98/11128 A1	3/19/1998	Dr. Karl Thomae GMBH		
	38	WO 98/17646 A1	4/30/1998	Dr. Karl Thomae GMBH		
	39	WO 98/44921 A1	10/15/1998	Merck & Co., Inc.		
	40	WO 99/52927 A1	10/21/1999	Arena Pharmaceuticals, Inc.		
	41	WO 00/23076 A1	4/27/2000	Suntory Limited		
	42	WO 00/56335 A1	9/28/2000	The Regents of the University of California		
	43	WO 00/69810 A1	11/23/2000	Novo Nordisk A/S		
	44	WO 01/44191 A1	6/21/2001	Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)		
	45	WO 01/87839 A1	11/22/2001	Astrazeneca AB		
	46	WO 02/079186 A2	10/10/2002	F. Hoffman-La Roche AG		
	47	WO 03/070246 A1	8/28/2003	Pfizer Products Inc.		
	48	WO 2005/112927 A	12/1/2005	Acadia Pharmaceuticals Inc.		
	49	WO 2006/036874 A1	4/6/2006	Acadia Pharmaceuticals Inc.		
/LW/	50	WO 2006/037043 A1	4/6/2006	Acadia Pharmaceuticals Inc.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
	Examiner	Williams, Leonard M.
SHEET 3 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	51	ADAM, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers. <i>Psychopharmacology</i> , 99:219-221.	
	52	ADELL, et al. 2005. Strategies for producing faster acting antidepressants. <i>Drug Discovery Today</i> , 10(8):578-585.	
	53	AKIN, et al. 2004. Decreased serotonin 5-HT _{2A} receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. <i>Neuropsychopharmacology</i> , 29:2081-2087.	
	54	ALVISI, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridine e dalla tribromidrina della glicerina ordinaria, <i>Gazz. Chem. Ital.</i> 22:158-168.	
	55	ANTILLA, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines. <i>Organic Letters</i> , 3(13):2077-2079.	
	56	ANTILLA, et al. 2002. The copper-catalyzed N-arylation of indoles. <i>J. Am. Chem. Soc.</i> , 124:11684-11688.	
	57	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin" <i>J. Medicinal Chemistry</i> , 17(7):736-739	
	58	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin" <i>J. Medicinal Chemistry</i> , 17(7):739-744	
	59	ARCHIBALD, et al., 1974 "1,4-Bis-(2-indol-3-ylethyl)piperdines" <i>J. Medicinal Chemistry</i> , 17(7):745-747	
	60	ARTICO, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. <i>Eur. J. Med. Chem.</i> , 27:219-228.	
	61	BAKSHI, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 271(2):787-794.	
	62	BASSUS, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique. <i>Eur. J. Med. Chem. - Chimica Therapeutica</i> , 9(4):416-423.	
	63	BHATIA, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones. <i>J. Med. Chem.</i> , 39:3938-3950.	
	64	BIAGI, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis <i>in vitro</i> . <i>Farmaco Ed. Sci.</i> , 43:597-612.	
	65	BLAKLEY, et al. 2001. Bidirectional changes in ethanol consumption in rats with site-specific antisense down-regulation of 5-hydroxytryptamine _{2A} receptors in brain. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299(1):277-289.	
	66	BLIER, et al. 2001. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. <i>Journal of Psychiatry & Neuroscience</i> , 26(1):37-43.	
	67	BLIER, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. <i>J. Clin. Psychiatry</i> , 66(suppl 8):30-40.	
	68	BROWN, et al. 1924. Catalytic alkylation of aniline, <i>J. Am. Chem. Soc.</i> , 46(8):1836-1839.	
/LW/	69	BUCHI et al. 1969. Synthesis of (±)-nuciferal. <i>J. Org. Chem.</i> , 34(4):1122-1123.	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 4 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	70	BUU-HOI, et al. 1951. Further studies in the alkylation of phenols and thiophenols, <i>J. Org. Chem.</i> , 16:988-994.	
	71	CACCHI, et al. 2003. Palladium-catalyzed reaction of aryl iodides with acetic anhydride. A carbon monoxide-free synthesis of acetophenones. <i>Organic Letters</i> , 5(3):289-291.	
	72	CARMAN, et al. 1998. A further synthesis of an analogue of the antifungal/antiherbivore lipid from avocado. <i>Aust. J. Chem.</i> , 51:955-959.	
	73	CAROON, et al. 1981. Synthesis and antihypertensive activity of a series of 8-substituted 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones. <i>J. Med. Chem.</i> , 24:1320-1328.	
	74	CARROLL, et al. 1992. Synthesis and muscarinic receptor activity of ester derivatives of 2-substituted 2-azabicyclo[2.2.1]heptan-5-ol and -6-ol. <i>J. Med. Chem.</i> , 35:2184-2191.	
	75	CATARZI, et al. 2001. Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173. <i>J. Med. Chem.</i> , 44:3157-3165.	
	76	Chemical Abstracts, 73:25305. BENKE, et al. 1970.	
	77	CHERKASOV, et al. 1985. Organothiophosphorus reagents in organic synthesis. <i>Tetrahedron</i> , 41(13):2567-2624.	
	78	CLARK et al. 1983. Antihypertensive 9-substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones. <i>J. Med. Chem.</i> , 26:855-861.	
	79	CLIFTON, et al. 1982. Arylethanolamines Derived from Salicyclamide with α - and β -Adrenoceptor Blocking Activities. Preparation of Labetalol, its Enantiomers, and Related Salicyclamides. <i>J. Med. Chem.</i> , 25:670-679.	
	80	DeCLERCK, et al. 1987. Increase in slow-wave sleep in humans with the serotonin-S ₂ antagonist ritanserine. <i>Current Therapeutic Research</i> , 41(4):427-432.	
	81	DUNN, et al. 1986. Analgetic and antiinflammatory 7-arylbenzofuran-5-ylacetic acids and 7-arylbenzothiophene-5-ylacetic acids. <i>J. Med. Chem.</i> , 29:2326-2329.	
	82	EMERSON, et al. 1938. The reductive alkylation of aniline. <i>J. Am. Chem. Soc.</i> , 60:2023-2025.	
	83	ERMAKOV, et al. 1981. Use of Mass spectrometry in structural and stereochemical studies. <i>Chemistry of Heterocyclic Compounds</i> , 1:72-77.	
	84	FINAR, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole, <i>J. Chem. Soc.</i> , pp. 2293-2298.	
	85	FISERA, et al. 1994. Synthesis of spiro-substituted 1,3-oxazines by a new sequence leading to spiroheterocycles. <i>Monatshefte für Chemie</i> , 125:909-919.	
	86	GAINETDINOV, et al. 2001. Genetic animal models: Focus on schizophrenia. <i>Trends in Neurosciences</i> , 24(9):527-533.	
/LW/	87	GAWLEY, R. E., & Aubé, J. 1996. <i>Principles of Asymmetric Synthesis</i> . New York: Pergamon.	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 5 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	88	GILLMAN, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>British Journal of Anaesthesia</i> , 95(4):434-441.	
	89	GOOREN, et al. 2001. Palladium-catalyzed synthesis of aryl ketones from boronic acids and carboxylic acids or anhydrides. <i>Angew. Chem. Int. Ed.</i> , 40:3458-3460.	
	90	GSTACH et al. 1990. Rearrangement of 3,3-disubstituted 1-aryl-4,5-dihydro-5-oxo-3H-1,2,4-triazolium tetrafluoroborates; Part 1. A versatile synthesis of 1,5-disubstituted 2-aryl-1,2-dihydro-3H-1,2,4-triazol-3-one tetrafluoroborates. <i>Synthesis</i> , pp. 803-808.	
	91	GUTHRIE, et al. 1993. The tetrahedral intermediate from the hydration of N-methylformanilide. <i>Can. J. Chem.</i> , 71:2109-2122.	
	92	HARPER, et al. 1964. The chemistry and pharmacology of some 4-aminopiperidines and their derivatives. <i>J. Med. Chem.</i> , 44:729-732.	
	93	HARTWIG, J. F. 1998. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: Scope and mechanism. <i>Angew. Chem. Int. Ed.</i> , 37:2047-2067.	
	94	HICKINBOTTOM, W. J. 1930. The preparation of secondary alkylaryl-amines and their purification. <i>J. Chem. Soc.</i> , pp. 992-994.	
	95	HIRST, et al. 1895. A method for preparing the formyl derivatives of the aromatic amines. <i>J. Chem. Soc.</i> , 67:829-831.	
	96	IDZIKOWSKI, et al. 1991. A dose response study examining the effects of ritanserin on human slow wave sleep. <i>Br. J. Clin. Pharmacol.</i> , 31:193-196.	
	97	IRIKURA et al., 1971 "New Anticancer Agents. 1. Synthesis and Biological Activities of 1-Acyl-2-, -3-, -4-substituted Benzamidopiperidines" <i>J. Medicinal Chemistry</i> 14(4): 357-361	
	98	JAEGER, et al. 1941. Two ketones of the stilboestrol group. <i>J. Chem. Soc.</i> , 744-747.	
	99	KANAYAMA, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine _{2A} receptor inhibitor: A randomized controlled trial. <i>J. Neurosurg: Spine</i> , 2:441-446.	
	100	KLAPARS, et al. 2001. A general and efficient copper catalyst for the amidation of aryl halides and the N-arylation of nitrogen heterocycles. <i>J. Am. Chem. Soc.</i> , 123:7727-7729.	
	101	KLAPARS, et al. 2002. A general and efficient copper catalyst for the amidation of aryl halides. <i>J. Am. Chem. Soc.</i> , 124:7421-7428.	
	102	KUEHNE, et al. 1991(a). Enantioselective syntheses of vinblastine, leurosine, vincosine, and 20'-epi-vincosine. <i>J. Org. Chem.</i> , 56(2):513-528.	
	103	KUEHNE, et al. 1991(b). Total syntheses of Yohimbe alkaloids, with stereoselection for the normal, allo, and 3-epiallo series, based on annulations of 4-methoxy-1,2-dihydropyridones. <i>J. Org. Chem.</i> , 56(8):2701-2712.	
✓	104	KWONG, et al. 2002(a). Copper-catalyzed coupling of alkylamines and aryl iodides: An efficient system even in an air atmosphere. <i>Organic Letters</i> , 4(4):581-584.	
/LW/	105	KWONG, et al. 2002(b). A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols. <i>Organic Letters</i> , 4(20):3517-3520.	

Examiner Signature /Leonard Williams/ (09/30/2007)

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 6 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	106	KWONG, et al. 2003. Mild and efficient copper-catalyzed amination of aryl bromides and primary alkylamines. <i>Organic Letters</i> , 5(6):793-796.	
	107	LANDINI, et al. 1974. A convenient synthesis of primary and secondary dialkyl and aryl alkyl sulfides in the presence of phase-transfer catalysts. <i>Synthesis</i> , pp. 565-566.	
	108	LANDOLT, et al. 1999. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. <i>Neuropsychopharmacology</i> , 21(3):455-466.	
	109	LI, G. Y. 2002. Highly active, air-stable palladium catalysts for the C-C and C-S bond-forming reactions of vinyl and aryl chlorides: Use of commercially available [(t-Bu) ₂ P(OH)] ₂ PdCl ₂ , [(t-Bu) ₂ P(OH)PdCl ₂] ₂ , and [(t-Bu) ₂ PO...H...OP(t-Bu) ₂]PdCl ₂ as catalysts. <i>J. Org. Chem.</i> , 67:3643-3650.	
	110	LOWE, et al. 1994. Aza-tricyclic substance P antagonists. <i>J. Med. Chem.</i> , 37:2831-2840.	
	111	MANSBACH, et al. 1988. Dopaminergic stimulation disrupts sensorimotor gating in the rat. <i>Psychopharmacology</i> , 94:507-514.	
	112	MAREK, et al. 2003. Synergistic action of 5-HT _{2A} antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. <i>Neuropsychopharmacology</i> , 28:402-412.	
	113	MAREK, et al. 2005. The selective 5-HT _{2A} receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. <i>Neuropsychopharmacology</i> , 30:2205-2215.	
	114	MAVUNKEL, et al. 1996. Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system. <i>J. Med. Chem.</i> , 39:3169-3173.	
	115	MAYER, et al. 2003. Ritanserin improves sleep quality in narcolepsy. <i>Pharmacopsychiatry</i> , 364:150-155.	
	116	MELTZER, H. Y. 1999. The role of serotonin in antipsychotic drug action. <i>Neuropsychopharmacology</i> , 21(2S):106S-115S.	
	117	MENG, et al. 1991. Synthetic approaches toward glidobamine, the core structure of the glidobactin antibiotics. <i>Tetrahedron</i> , 47(32):62510-6264.	
	118	MICOVIC, et al. 1991. A simple method for preparation of secondary aromatic amines. <i>Synthesis</i> , 11:1043-1045.	
	119	MIYATA, et al. 2000. Sarpogrelate, a selective 5-HT _{2A} serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. <i>Journal of Cardiovascular Pharmacology</i> , 35(2) 294-301.	
	120	MÖHRLE, et al. 1990. Sodium mercury edetate dehydrogenation of N-aliphatic substituted 1,2,3,6-tetrahydropyridine derivatives. <i>Arch. Pharm. (Weinheim)</i> , 323:109-115.	
	121	MOUNE, et al. 1997. Total synthesis of dolatrienoic acid: A subunit of dolastatin 14. <i>J. Org. Chem.</i> , 62:3332-3339.	
✓	122	MULLEN et al. 2000. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. <i>J. Med. Chem.</i> , 43:4045-4050.	
/LW/	123	MURI, et al. 1998. Synthesis of new benzylic ethers of oximes derived from 1-phenyl-pyrazole compounds. <i>Synthetic Communications</i> , 28(7):1299-1321.	

Examiner Signature /Leonard Williams/ (09/30/2007)

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 7 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	124	NIGAM, et al. 1957a. Studies with acetylenes. Part II. Some reactions of Grignard reagents with propargylic halides. Model linoleic and linolenic acid systems. <i>J. Chem. Soc.</i> , pp. 3868-3873.	
	125	NIGAM, et al. 1957b. The conversion of fatty acids into aldehydes. <i>J. Chem. Soc.</i> , pp.3320-3321.	
	126	OGAWA, et al. 2005. Effects of R-102444 and its active metabolite R-96544, selective 5-HT _{2A} receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT _{2A} receptors in the development of experimental pancreatitis. <i>European Journal of Pharmacology</i> , 521:156-163	
	127	OLAH, et al. 1956. Notiz über die <i>n</i> -formylierung von aminen mit formylfluorid. <i>Chem. Ber.</i> , 89:2211-2212.	
	128	OLD, et al. 2002. Efficient palladium-catalyzed <i>n</i> -arylation of indoles. <i>Organic Letters</i> , 2(10):1403-1406.	
	129	PAIVA, et al. 1988. Effects of ritanserlin on sleep disturbances of dysthymic patients. <i>Psychopharmacology</i> , 96:395-399.	
	130	PATEL, et al. 2004. The highly selective 5-hydroxytryptamine (5-HT) _{2A} receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. <i>Synapse</i> , 52:73-75.	
	131	PIERCE, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine _{2A} receptors on sympathetic efferent terminals. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 275(1):502-508.	
	132	READ, W. T. 1922. Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin(nirvanol). <i>J. Am. Chem. Soc.</i> , 44:1746-1755.	
	133	RICCI, A. 2000. <i>Modern Animation Methods</i> . New York: Wiley-VCH.	
	134	RICE, et al. 1955. Raney nickel catalyzed <i>n</i> -alkylation of aniline and benzidine with alcohols. <i>J. Am. Chem. Soc.</i> , 77:4052-4054.	
	135	RUBIRALTA, M., Giralt, E., & Diez, A. 1991. <i>Studies in Organic Chemistry 43. Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its Derivatives</i> . New York: Elsevier.	
	136	SCHEIBYE, et al. 1978. Studies on organophosphorus compounds XXI. The dimer of <i>p</i> -methoxyphenylthionophosphine sulfide as thiation reagent. A new route to thiocarboxamides. <i>Bull. Soc. Chim. Belg.</i> , 87:229-238.	
	137	SCHINS, et al. 2003. Increased coronary events in depressed cardiovascular patients: 5-HT _{2A} receptor as missing link? <i>Psychosomatic Medicine</i> , 65:729-737.	
	138	SCRETTAS, et al. 1978. Hydrolithiation of α -olefins by a regiospecific two-step process. Transformation of alkyl phenyl sulfides to alkyllithium reagents. <i>J. Org. Chem.</i> , 43(6):1064-1071.	
	139	SHARPLEY, et al. 1994. Slow wave sleep in humans: Role of 5-HT _{2A} and 5-HT _{2C} receptors. <i>Neuropharmacology</i> , 33(3/4):467-471.	
/LW/	140	SMITH, et al. 1995. New spiroperidines as potent and selective non-peptide tachykinin NK ₂ receptor antagonists. <i>J. Med. Chem.</i> , 38(19):3772-3779.	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
	Examiner	Williams, Leonard M.
SHEET 8 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	141	STEFANCICH, et al. 1984. Agenti antiinfiammatori non-steroidi: Nota III - sintesi ed attività analgesica-antiinfiammatoria di 4-(pirrol-1-il)-fenilacetamidi e di 4-(pirrol-1-il)fenetilamine. <i>Farmaco Ed. Sci.</i> , 39(9):752-764.	
	142	STRYJER, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT _{2A} antagonist trazodone. <i>Clinical Neuropharmacology</i> , 26(3):137-141.	
	143	TOLSTIKOV et al. 1991 "Synthesis and Reactivity of N-substituted aminoamides, antiarrhythmic and local anaesthetic activity" <i>Russian Chemical Reviews</i> 60(4):420-434	
	144	TSUKAMOTO, et al. 1995. Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M ₁ muscarinic agonists. <i>Chem. Pharm. Bull.</i> , 43(9):1523-1529.	
	145	VAN LAAR, et al. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-HT _{2A/2C} antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology</i> , 154:189-197.	
	146	VARMA, et al. 1999. Microwave-accelerated solvent-free synthesis of thioketones, thiolactones, thioamides, thionoesters, and thioflavonoids. <i>Organic Letters</i> , 1(5):697-700.	
	147	VIOLA, et al. 2002. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. <i>Clinical Neurophysiology</i> , 113:429-434.	
	148	VOGEL, A. I. 1948. Physical properties and chemical constitution. Part XIX. Five-membered and six-membered carbon rings. <i>J. Chem. Soc.</i> , pp. 1809-1813.	
	149	VOGL, et al. 2002. Palladium-catalyzed monoarylation of nitroalkanes. <i>J. Org. Chem.</i> , 67(1):106-111.	
	150	WADE, et al. 2000. Application of base cleavable safety catch linkers to solid phase library production. <i>J. Comb. Chem.</i> , 2(3):266-275.	
	151	WHITMORE, et al. 1942. Abnormal Grignard reactions. XII. Sterically hindered aliphatic carbonyl compounds. II. Ketones containing the dineopentylcarbonyl group. <i>J. Am. Chem. Soc.</i> , 64:1247-1251.	
	152	WHITMORE, et al. 1947. Higher hydrocarbons. IV. Six phenyleicosanes and six cyclohexyleicosanes. <i>J. Am. Chem. Soc.</i> , 69:235-237.	
	153	WOLF, V. V. 1952. Über alkin-amine I. Aryl-propargyl-amine. <i>Liebigs Ann. Chem.</i> , 576:35-45.	
	154	WOLFE, et al. 1996. An improved catalyst system for aromatic carbon-nitrogen bond formation: The possible involvement of bis(phosphine) palladium complexes as key intermediates. <i>J. Am. Chem. Soc.</i> , 118:7215-7216.	
	155	YAMADA, et al. 1998. Alternative synthesis of TTF donors with a dioxolane ring, and synthesis of their dithiolane and oxathiolane analogues. <i>Tetrahedron Letters</i> , 39:7709-7712.	
	156	YANG, et al. 1999. Palladium-catalyzed amination of aryl halides and sulfonates. <i>Journal of Organometallic Chemistry</i> , 576:125-146.	
✓	157	YASUHARA, et al. 2000. An activated phosphate for an efficient amide and peptide coupling reagent. <i>J. Chem. Soc., Perkin Trans. 1</i> , 17:2901-2902.	
/LW/	158	YIN, et al. 2002. Pd-catalyzed intermolecular amidation of aryl halides: The discovery that xantphos can be trans-chelating in a palladium complex. <i>J. Am. Chem. Soc.</i> , 124:6043-6048.	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 9 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	159	Notice of Allowance and Fee(s) Due and Notice of Allowability dated May 15, 1997, from Application No. 08/273,669 filed July 12, 1994, now U.S. Pat. No. 5,707,798.	
	160	Office Action dated March 27, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	161	Notice of Allowance and Fee(s) Due and Notice of Allowability dated September 4, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	162	Office Action dated September 14, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	163	Interview Summary dated November 17, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	164	International Search Report dated July 17, 2001 for PCT/US01/07187.	
	165	Written Opinion dated November 22, 2002 for PCT/US01/07187.	
	166	Office Action dated February 28, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	167	Notice of Allowance and Fee(s) Due and Notice of Allowability dated November 20, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	168	Office Action dated January 17, 2006, from Application No. 11/154,083 filed June 26, 2005.	
	169	International Search Report dated May 8, 2003 for PCT/US02/41476.	
	170	International Search Report dated January 30, 2006, for PCT/US2005/034813	
	171	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034813.	
	172	International Search Report dated January 30, 2006, for PCT/US2005/034376.	
	173	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034376.	
	174	Office Action dated November 4, 2004, from Application No. 10/601,070 filed June 20, 2003	
	175	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034376.	
✓	176	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034813.	
/LW/	177	Office Action dated April 6, 2007, from Application No. 11/418,322 filed May 3, 2006.	

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 10 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	178	Office Action dated May 8, 2007, from Application No. 11/417,866 filed May 3, 2006.	
/LW/	179	Notice of Allowance and Fee(s) Due and Notice of Allowability dated March 5, 2007, from Application No. 10/601,070 filed June 20, 2003.	
/LW/	180	Office Action dated February 5, 2007, from Application No. 11/299,566 filed December 12, 2005	
/LW/	181	Notice of Allowance and Fee(s) Due and Notice of Allowability dated June 19, 2007, from application No. 11/418,322 filed May 3, 2006	

4095912:sad
080307

Examiner Signature /Leonard Williams/ (09/30/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.



PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/759,561
Filing Date	January 15, 2004
First Named Inventor	David M. Weiner, et al.
Art Unit	1617
Examiner	Williams, Leonard M.
Attorney Docket No.	ACADIA.030A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/LW/	1	6,150,393	11-21-2000	Behan, et al.	
/LW/	2	6,479,480	11-12-2002	Moyes, et al.	
/LW/	3	6,486,153	11-26-2002	Castro Pineiro, et al.	
/LW/	4	2002/0156068	10-24-2002	Behan et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/LW/	5	WO 2002/076464 A1	10-03-2002	Arena Pharmaceuticals, Inc.		
/LW/	6	WO 2003/062206 A2	07-31-2003	Arena Pharmaceuticals, Inc.		
/LW/	7	WO 2004/039322 A2	05-13-2004	Micro, Inc.		
/LW/	8	WO 2004/064738 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
/LW/	9	WO 2004/064753 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
/LW/	10	WO 2005/053796 A1	06-16-2005	B&B Beheer NV		
/LW/	11	WO 2005/063254 A2	07-14-2005	Acadia Pharmaceuticals Inc.		
/LW/	12	WO 2006/104826	10-05-2006	Merck & Co., Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	13	International Search Report and Written Opinion from PCT/US2005/017808 mailed September 29, 2005.	

4096691:sad
080307

Examiner Signature	/Leonard Williams/ (10/01/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	Weiner, et al.
	Art Unit	1617
SHEET 1 OF 3		Examiner Williams, Leonard M.
		Attorney Docket No. ACADIA.030A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/LW/	1	4,853,394	08-01-1989	King, et al.	
	2	5,216,165	06-01-1993	Mobilio, et al.	
	3	6,756,393	06-29-2004	Andersson, et al.	
	4	6,815,458	11-09-2004	Andersson, et al.	
	5	6,911,452	06-28-2005	Schlienger	
	6	7,115,634	10-03-2006	Thurieu, et al.	
	7	2004/0006081	01-08-2004	Burrows, et al.	
	8	2004/0106600 A1	06-03-2004	Andersson, et al.	
	9	2005/0014757 A1	01-20-2005	Andersson, et al.	
	10	2005/0256108 A1	11-17-2005	Schlienger	
	11	2006/0094758 A1	05-04-2006	Andersson, et al.	
	12	2006/0194778 A1	08-31-2006	Andersson, et al.	
	13	2006/0194834 A1	08-31-2006	Andersson, et al.	
	14	2006/0199794 A1	09-07-2006	Schlienger	
	15	2006/0199818 A1	09-07-2006	Andersson, et al.	
	16	2006/0205710 A1	09-14-2006	Schlienger, et al.	
	17	2006/0205722 A1	09-14-2006	Andersson, et al.	
	18	2006/0199842 A1	09-07-2006	Weiner, et al.	
	19	2006/0264465 A1	11-23-2006	Weiner, et al.	
/LW/	20	2006/0264466 A1	11-23-2006	Weiner, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/LW/	21	WO 94/27967 A1	12-18-1994	Smithkline Beecham Laboratoires Pharmaceutiques		
/LW/	22	WO 97/38665 A2	10-23-1997	Merck & Co., Inc.		
/LW/	23	WO 97/38984 A1	10-23-1997	The Dupont Merck Pharmaceutical Company		

Examiner Signature	/Leonard Williams/ (10/01/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 2 OF 3	Attorney Docket No.	ACADIA.030A

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/LW/	24	WO 98/50534 A1	11-12-1998	Smithkline Beecham Corporation		
/LW/	25	WO 00/59497 A1	10-12-2000	Merck & Co., Inc.		
/LW/	26	WO 01/66521 A1	09-13-2001	Acadia Pharmaceuticals, Inc.		
/LW/	27	WO 03/057698 A2	07-17-2003	Acadia Pharmaceuticals, Inc.		
/LW/	28	WO 03/057698 A3	07-17-2003	Acadia Pharmaceuticals, Inc.		
/LW/	29	WO 03/086400 A1	10-23-2003	Glaxo Group Limited		
/LW/	30	WO 2004/000808 A2	12-31-2003	Acadia Pharmaceuticals Inc.		
/LW/	31	WO 2004/000808 A3	12-31-2003	Acadia Pharmaceuticals Inc.		
/LW/	32	EP 0 260 070 B1	08-11-1993	H. Lundbeck A/S		
/LW/	33	FR 2,802,206 A1	06-15-2001	Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	34	KALGUTKAR, et al. 1995. Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. <i>Medicinal Research Reviews</i> , 15(4)325-388. XP002034298.	
/LW/	35	Office Action dated April 25, 2002, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
/LW/	36	Office Action dated January 21, 2003, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
/LW/	37	Office Action dated July 15, 2003, from Application No. 09/800,096, now U.S. Pat. No. 6,815,458.	
/LW/	38	Notice of Allowability dated December 8, 2003, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	
/LW/	39	Notice of Allowance and Fee(s) Due and Notice of Allowability dated December 5, 2003, from Application No. 10/409,782 filed April 7, 2003, now U.S. Pat. No. 6,756,393.	
/LW/	40	International Preliminary Examination Report dated March 18, 2003, for PCT/US01/07187.	

Examiner Signature	/Leonard Williams/ (10/01/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

T¹ - Place a check mark in this area when an English language Translation is attached.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 3 OF 3	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	41	Office Action dated May 21, 2004, from Application No. 10/329,719 filed December 23, 2002, now U.S. Pat. No. 6,911,452.	
/LW/	42	Notice of Allowance and Fee(s) Due and Notice of Allowability dated February 11, 2005, from Application No. 10/329,719 filed December 23, 2002, now U.S. Pat. No. 6,911,452.	
/LW/	43	Office Action dated June 26, 2006, from Application No. 11/154,083 filed June 26, 2005.	
/LW/	44	Notice of Allowability, Notice of Allowance and Fee(s) Due, and Interview Summary dated December 15, 2006, from Application No. 11/154,083 filed June 16, 2005.	
/LW/	45	Office Action dated October 5, 2006, from Application No. 11/418,322 filed May 3, 2006.	
/LW/	46	Office Action dated January 23, 2007, from Application No. 11/418,322 filed May 3, 2006.	
/LW/	47	Written Opinion dated September 9, 2003, for PCT/US02/41476.	
/LW/	48	International Preliminary Examination Report dated January 15, 2004, for PCT/US02/41476.	
/LW/	49	Office Action dated November 4, 2004, from Application No. 10/601,070 filed June 20, 2003.	
/LW/	50	Notice of Allowance and Fee(s) Due and Notice of Allowability dated July 12, 2005, from Application No. 10/601,070 filed June 20, 2003.	
/LW/	51	Notice of Allowance and Fee(s) Due and Notice of Allowability dated March 29, 2006, from Application No. 10/601,070 filed June 20, 2003.	
/LW/	52	International Search Report for PCT/US03/19797 dated December 3, 2003.	
/LW/	53	Written Opinion for PCT/US03/19797 dated April 5, 2004.	
/LW/	54	International Preliminary Examination Report for PCT/US03/19797 dated July 28, 2004.	
/LW/	55	International Search Report for PCT/US2004/001234 dated September 8, 2004.	
/LW/	56	International Written Opinion for PCT/US2004/001234 dated September 8, 2004.	
/LW/	57	International Preliminary Report on Patentability for PCT/US2004/001234 dated April 14, 2005.	

3358156:sad2
012907

Examiner Signature	/Leonard Williams/ (10/01/2007)	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

T¹ - Place a check mark in this area when an English language Translation is attached.



PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner
	Art Unit	1614
	Examiner	Not Yet Assigned
Attorney Docket No.		ACADIA.030A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/LW/	1	US 5,877,173 A	03-02-1999	Farber et al.	
/LW/	2	US 3,983,234 A	09-28-1976	Campbell	
/LW/	3	US 2002/165225 A1	11-07-02	Kankan et al.	
/LW/	4	US 6,358,698 B1	03-19-02	Brann et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/LW/	5	WO 0166521	09-13-01	Andersson et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/LW/	6	Friedman, J.H., "Clozapine Treatment of Psychosis in Patients with Tardive Dystonia: Report of Three Cases." (Movement Disorders Official Journal of the Movement Disorder Society), May 1994, vol. 9, no. 3:321-324.	
/LW/	7	Yoshida, K. et al. "Marked Improvement of Tardive Dystonia After Replacing Haloperidol with Risperidone in a Schizophrenic Patient." (Clinical Neuropharmacology), 1998, vol.21, no. 1: 68-69.	
/LW/	8	Delecluse, F., et al. "A Case of Tardive Tremor Successfully Treated with Clozapine." (Movement Disorders Official Journal of the Movement Disorder Society), September 1998, vol. 13, no. 5: 846-847.	
/LW/	9	Factor, S.A., et al. "Clozapine Prevents Recurrence of Psychosis in Parkinson's Disease." (Movement Disorders Official Journal of the Movement Disorder Society), 1992, vol. 7, no. 2: 125-131.	
/LW/	10	Factor, et al. "Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease: Results of the 12 Week Open Label Extension in the PSYCLOPS Trial." (Movement Disorders Official Journal of the Movement Disorder Society), January 2001, vol. 16, no.1: 135-139.	
/LW/	11	Herrick-Davis, et al. "Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors" (The Journal of Pharmacology and Experimental Therapeutics), October 2000, vol. 295, no. 1: 226-232.	
/LW/	12	Delecluse, et al. "A Case of Tardive Tremor Successfully Treated with Clozapine" (Movement Disorders Official Journal of the Movement Disorder Society), 1998, vol. 13, no. 5: 846-847.	
/LW/	13	International Search Report mailed on September 8, 2004	
/LW/	14	Written Opinion mailed on December 15, 2004	

S:\DOCS\REM\REM-2025.DOC\vea/011305

Examiner Signature	/Leonard Williams/ (10/01/2007)	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

T¹ - Place a check mark in this area when an English language Translation is attached.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ACADIA.030AAPPLICATION NO.
10/759,581INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)


APPLICANT
Weiner, et al.FILING DATE
January 15, 2004GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
/LW/	1	Barchas, et al., <i>Serotonin and Behavior</i> , pp. 483-498, 523-560 (1973)
/LW/	2	Birkmayer, W., Danielczyk, W., Neumayer, E., and Riederer, P., "Nucleus Ruber and L-Dopa Psychosis: Biochemical Post-Mortem Findings," <i>Journal of Neural Transmission</i> , 35:93-116 (1974)
/LW/	3	Bouillin, <i>Serotonin In Mental Abnormalities</i> , pp. 119-181 (1978)
/LW/	4	Eichelbaum, et al., "Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists: Influence of Pharmacogenetics on Drug Disposition and Response," <i>Clin. Exp. Pharmacol. Physiol.</i> , 23:983-985 (1996)

S:\DOCS\IREM\REM-1330.DOC:sad
051304

EXAMINER /Leonard Williams/ (10/01/2007)	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.030A	APPLICATION NO. 10/759,561
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Weiner, et al.	
		FILING DATE January 15, 2004	GROUP Unknown




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/LW/	1	5,707,798	01/13/98	Brann			
/LW/	2	5,912,132	06/15/99	Brann			
/LW/	3	5,955,281	09/21/99	Brann			
/LW/	4	2002/0004513	01/10/02	Andersson et al.			
/LW/	5	6,358,698	03/19/02	Weiner et al.			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
/LW/	6	Barnes, N.M., et al., "A review of central 5-HT receptors and their fuction," <i>Neuropharmacology</i> , 38:1083-1152 (1999)					
/LW/	7	Barr, A.J., et al., "Agonist-independent Activation of G _z by the 5-Hydroxytryptamine _{1A} Receptor Co-expressed in <i>Spodoptera frugiperda</i> Cells," <i>J. Biol. Chem.</i> 272:32979-87 (1997).					
/LW/	8	Bennett, J., P., Landow, E., R., and Shuh, L., A. (1993) "Suppression of dyskinesias in advanced Parkinson's Disease. II Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms," <i>Neurology</i> , 43: 1551-1555.					
/LW/	9	Bibbiani, F., Oh, F., D., and Chase, T., C. (2001) "Serotonin 5-HT _{1A} agonist improves motor complications in rodent and primate parkinsonian models," <i>Neurology</i> , 57: 1829-1834.					
/LW/	10	Bond, et al., "Physiological effects of inverse agonists in transgenic mice with myocardial overexpresion of the β_2 -adrenoceptor," <i>Nature</i> 374:272 (1995).					
/LW/	11	Brann, "Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes," <i>Chem. Abstr.</i> 128:111548 (1998) and citations therein.					
/LW/	12	Butcher, L., Engel, J., and Fuxe, K. (1970) "L-Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition," <i>J. Pharm. Pharmac.</i> , 22: 313-316.					
/LW/	13	Cerione et al., "The Mammalian β_2 -Adrenergic Receptor: Reconstitution of Functional Interactions between Pure Receptor and Pure Stimulatory Nucleotide Binding Protein of the Adenylate Cyclase System," <i>Biochemistry</i> 23:4519-25 (1984)					
/LW/	14	Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A., M., and Agid, Y. (1997) "Low-dose clozapine improves dyskinesias in Parkinson's disease," <i>Neurology</i> , 48: 658-662.					
/LW/	15	Everett, G., M., and Borcharding, J., W. (1970) "L-dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice," <i>Nature</i> , 168: 849-850.					
/LW/	16	The French Clozapine Study Group (1999) "Clozapine in drug-induced psychosis in Parkinson's disease," <i>Lancet</i> , 353: 2041-2042.					
/LW/	17	Friedman, J., H., and Factor, S., A. (2000) "Atypical Antipsychotics in the Treatment of Drug-Induced Psychosis in Parkinson's Disease," <i>Mov. Disord</i> , 15(2): 201-211.					
/LW/	18	Fuller, R.W., "Drugs Acting on Serotonergic Neuronal Systems," <i>Biology of Serotonergic Transmission</i> , 1982, pp. 221-247.					

EXAMINER	/Leonard Williams/ (10/01/2007)	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.030A	APPLICATION NO. 10/759,561
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Weiner, et al.	
		FILING DATE January 15, 2004	GROUP Unknown



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
/LW/	19	Gamma, A., Buck, A., Berthold, T., Liechti, M., E., and Vollenweider, F., X. (2000) "3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H ₂ ¹⁵ O]-PET in Healthy Humans," <i>Neuropsychopharmacology</i> , 23(4): 388-395.
/LW/	20	Gershon, et al., "5-Hydroxytryptamine and enteric neurones," <i>The Peripheral Actions of 5-Hydroxytryptamine</i> , pp. 247-273 (1989)
/LW/	21	Glennon, "Serotonin Receptors: Clinical Implications," <i>Neurosci. Biobehavioral Rev.</i> , 14:35-47 (1990)
/LW/	22	Julius et al., "The 5HT ₂ receptor defines a family of structurally distinct but functionally conserved serotonin receptors," <i>Proc. Natl. Acad. Sci. USA</i> 87:928-932
/LW/	23	Leysen, J., E., Niemegeers, C., J., Tollenaraere, J., P., and Laduron, P., M. (1978) "Serotonergic component of neuroleptic receptors," <i>Nature (Lond)</i> 272: 168-171.
/LW/	24	Liechti, M., E., Geyer, M., A., Hell, D., and Vollenwieder, F., X. (2001) "Effects of MDMA(ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin," <i>Neuropsychopharmacology</i> , 24(3): 240-252.
/LW/	25	Linder, "Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency," <i>Clin. Chem.</i> 43:254-66 (1997)
/LW/	26	Meltzer, "The Role of Serotonin in Antipsychotic Drug Action," <i>Neuropsychopharmacology</i> , 21:106S-115S (1999)
/LW/	27	Meltzer, H., Y., Kennedy, J., Dai, J., Parsa, M., and Riley, D. (1995) "Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease. A High Potency Effect of Clozapine," <i>Neuropsychopharmacology</i> , 12(1): 39-45.
/LW/	28	Moulinier, A., "Récepteurs Centraux de la Sérotonine Principaux Aspects Fondamentaux et fonctionnels Applications Thérapeutiques," <i>Rev. Neurol.</i> 150:3-15, (1994)
/LW/	29	Ng, K., Y., Chase, T., N., Colburn, R., W., and Kopin, I., J., (1970) "L-Dopa Induced Release of Cerebral Monoamines," <i>Science</i> , 170: 76-77.
/LW/	30	Nordstrom, A., L., Farde, L., and Halldin, C. (1993) "High 5-HT ₂ receptor occupancy in clozapine treated patients as demonstrated by PET," <i>Psychopharmacology</i> , 110(3): 365-367.
/LW/	31	Pace et al., "A mutant α subunit of G ₁₂ induces neoplastic transformation of Rat-1 cells," <i>Proc. Natl. Acad. Sci. USA</i> 88:7031-35 (1991)
/LW/	32	The Parkinson Study Group (1999) "Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease," <i>New Eng. J. Med.</i> , 340(10): 757-763.
/LW/	33	Sadzot, B., Baraban, J., M., Glennon, R., A., Lyon, R., A., Leonhardt, S., Jan, C., R., and Tietler, M. (1989) "Hallucinogenic drug interactions at human brain 5-HT ₂ receptors; implications for treating LSD-induced hallucinogenesis," <i>Psychopharmacology</i> , 98(4): 495-499.
/LW/	34	Saltzman et al., "Cloning of the Human Serotonin 5-HT ₂ and 5-HT _{1C} Receptor Subtypes," <i>Biochem. Biophys. Res. Comm.</i> 181:1469-78
/LW/	35	Saxena, et al., "Cardiovascular Effects of Serotonin Agonists and Antagonists," <i>J. Cardiovascular Pharmacol.</i> 15: Supp. 7 (1990), pages S17-S34.
/LW/	36	Vallar et al., "Altered G _s and adenylate cyclase activity in human GH-secreting pituitary adenomas," <i>Nature</i> 330:556-58 (1987)
/LW/	37	Weiner, D., M., Burstein, E., S., Nash, N., Croston, G., E., Currier, E., A., Vanover, K., E., Harvey, S., C., Donohue, E., Hansen, H., C., Andersson, C., M., Spalding, T., A., Gibson, D., F., Krebs-Thomson, K., Powell, S., B., Geyer, M., A., Hacksell, U., and Brann, M., R. (2001) "5-Hydroxytryptamine _{2A} Receptor Inverse Agonists as Antipsychotics," <i>J Pharmacol Exp Ther.</i> , 299(1): 268-76.

S:\DOCS\REM\REM-1255.DOC:sad:041404

EXAMINER /Leonard Williams/ (10/01/2007)	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	